MTSL Issue 851 (dated 5/04/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #BMRN #CELG #ESPR #FPRX #INCY #IONS #MDCO #PCRX #SGMO #ZIOP
BIOINVEST Access to Management Webinar – Madrigal (MDGL)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Madrigal.
BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – FOURIER IS ACTUALLY MORE POSITIVE FOR INCLISIRAN THAN BEFORE – Being the first to market is sometimes a double edged sword and is certainly the case with the Amgen’s Repatha (and REGN/SNY’s Praluent). We were at the ACC where the FOURIER* data was presented on Friday.
BIOINVEST BREAKING NEWS – Nektar (NKTR) – NKTR-181 Successful In Phase III SUMMIT-07 Trial & Sets The Stage For A Revolution In Pain Drugs – Raising BUY and TARGET PRICE
The SUMMIT-07 trial met its primary endpoint demonstrating highly significant improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Moreover, the safety and tolerability of ‘181 in SUMMIT supports its breakthrough profile for moderate-to-severe pain relief without the abuse and addiction that has caused the opioid epidemic of today
BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – Inclisiran FDA Path Clear After End of Phase II Meeting – Lower Risk, Value Enhanced – The Medicines Company announced that the primary endpoint of the Phase III registrational trial will be LDL-C levels. This is a major positive for MDCO – significantly reduces the risk and increases the value of Inclisiran.
MTSL Issue 849 (dated 3/30/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ANTH #ESPR #IONS #NKTR #SGMO #ZIOP
MTSL Issue 848 (dated 3/16/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #ESPR #IONS #XON #MDCO #OGXI #PCRX
MTSL Issue 846 (dated 2/16/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR (new) #INCY #IONS
MTSL Issue 850 (dated 4/20/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #INCY #MDGL #NKTR #ZIOP
BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60
This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.
MTSL Issue 847 (dated 3/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #FPRX #INCY #XON #IONS #MDCO #NKTR #PCRX #SGMO
MTSL Issue 845 (dated 2/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #XON #MDCO #NVAX #PCRX
